CLSA Applauds Governor Brown for Signing SB 1121, Legislation That Protects Clinical Trials and Patient Access in California

SB 1121 Contains Common Sense, Bipartisan Fix to Unintended Consequences of Data Privacy Bill

Sacramento, CA – September 24, 2018California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today applauded Gov. Jerry Brown for signing Senate Bill 1121, legislation that helps protect clinical trials conducted in California, which are the lifeblood of new and innovative medicines to treat patients in need. SB 1121 was approved by the California Legislature earlier this year and signed yesterday, Sept. 23, by Brown. The following statement can be attributed to Sara Radcliffe, President & CEO, CLSA:

“On behalf of California’s life sciences innovators, a sector with over 3,000 firms employing 300,000 people, California Life Sciences Association (CLSA) applauds Governor Jerry Brown for signing Senate Bill 1121, critical legislation that will preserve California patients’ access to clinical trials and allow innovative research to continue. By signing SB 1121 into law, California life sciences companies can continue doing what they do best – finding cures and treatments for the patients that need them. This legislative fix ensures that conducting clinical trials in the state will not be hindered by the potential unintended consequences of California’s sweeping data privacy law, AB 375.”

CLSA launched a digital campaign and grassroots effort to urge the Governor to sign SB 1121. Click here to learn more about the bill.


  • Learn more about the California life sciences industry
  • View CLSA’s Legislative Action Center
  • Watch CLSA’s Faces of California Biomedical Innovation Web Series
  • View CLSA’s Advocacy Priorities
  • View upcoming CLSA events

About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.

Media Contact:
California Life Sciences Association (CLSA)
Will Zasadny | Director, Communications | 619-961-8848